[en] PURPOSE: Second malignant neoplasms (SMNs) after diagnosis of childhood acute lymphoblastic leukemia (ALL) are rare events. PATIENTS AND METHODS: We analyzed data on risk factors and outcomes of 642 children with SMNs occurring after treatment for ALL from 18 collaborative study groups between 1980 and 2007. RESULTS: Acute myeloid leukemia (AML; n = 186), myelodysplastic syndrome (MDS; n = 69), and nonmeningioma brain tumor (n = 116) were the most common types of SMNs and had the poorest outcome (5-year survival rate, 18.1% +/- 2.9%, 31.1% +/- 6.2%, and 18.3% +/- 3.8%, respectively). Five-year survival estimates for AML were 11.2% +/- 2.9% for 125 patients diagnosed before 2000 and 34.1% +/- 6.3% for 61 patients diagnosed after 2000 (P < .001); 5-year survival estimates for MDS were 17.1% +/- 6.4% (n = 36) and 48.2% +/- 10.6% (n = 33; P = .005). Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies after adjusting for waiting time to transplantation. Five-year survival rates were above 90% for patients with meningioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gland tumor, and 68.5% +/- 6.4% for those with non-Hodgkin lymphoma. Eighty-nine percent of patients with brain tumors had received cranial irradiation. Solid tumors were associated with cyclophosphamide exposure, and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methotrexate of at least 25 mg/m(2) per week and mercaptopurine of at least 75 mg/m(2) per day. Myeloid malignancies with monosomy 7/5q- were associated with high hyperdiploid ALL karyotypes, whereas 11q23/MLL-rearranged AML or MDS was associated with ALL harboring translocations of t(9;22), t(4;11), t(1;19), and t(12;21) (P = .03). CONCLUSION: SMNs, except for brain tumors, AML, and MDS, have outcomes similar to their primary counterparts.
Disciplines :
Hematology Oncology Pediatrics
Author, co-author :
Schmiegelow, Kjeld
Levinsen, Mette Frandsen
Attarbaschi, Andishe
Baruchel, Andre
Devidas, Meenakshi
Escherich, Gabriele
Gibson, Brenda
Heydrich, Christiane
Horibe, Keizo
Ishida, Yasushi
Liang, Der-Cherng
Locatelli, Franco
Michel, Gerard
Pieters, Rob
Piette, Caroline ; Université de Liège > Département des sciences cliniques > Pédiatrie
Hijiya N, Hudson MM, Lensing S, et al: Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297:1207-1215, 2007
Schmiegelow K, Al-Modhwahi I, Andersen MK, et al: Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Blood 113:6077-6084, 2009
Prucker C, Attarbaschi A, Peters C, et al: Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: A population-based analysis of the Austrian Berlin-Frankfurt-Münster study group. Leukemia 23:1264-1269, 2009
Lund B, Åsberg A, Heyman M, et al: Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 56:551-559, 2011
Schmiegelow K, Forestier E, Hellebostad M, et al: Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24:345-354, 2010
Kamps WA, van der Pal-de Bruin KM, Veer-man AJ, et al: Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 24:309-319, 2010
Pui CH, Pei D, Sandlund JT, et al: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 24:371-382, 2010
Tsuchida M, Ohara A, Manabe A, et al: Long-term results of Tokyo Children’s Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia 24:383-396, 2010
Tsurusawa M, Shimomura Y, Asami K, et al: Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 24:335-344, 2010
Silverman LB, Stevenson KE, O’Brien JE, et al: Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 24:320-334, 2010
Conter V, Aricò M, Basso G, et al: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 24:255-264, 2010
Stary J, Jabali Y, Trka J, et al: Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia 24: 425-428, 2010
Gaynon PS, Angiolillo AL, Carroll WL, et al: Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children’s Oncology Group Report. Leukemia 24:285-297, 2010
Salzer WL, Devidas M, Carroll WL, et al: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children’s Oncology Group. Leukemia 24:355-370, 2010
Möricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010
Escherich G, Horstmann MA, Zimmermann M, et al: Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82, 85, 89, 92 and 97. Leukemia 24:298-308, 2010
Mitchell C, Richards S, Harrison CJ, et al: Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 24:406-418, 2010
Olsen JH, Möller T, Anderson H, et al: Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 101:806-813, 2009
Aricò M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998-1006, 2000
Pui CH, Gaynon PS, Boyett JM, et al: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915, 2002
Nachman JB, Heerema NA, Sather H, et al: Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110:1112-1115, 2007
Aricò M, Schrappe M, Hunger SP, et al: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 28:4755-4761, 2010
Schrappe M, Hunger SP, Pui CH, et al: Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366:1371-1381, 2012
Liang DC, Yang CP, Lin DT, et al: Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 24:397-405, 2010
Stark B, Nirel R, Avrahami G, et al: Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 24:419-424, 2010
Schrappe M, Nachman J, Hunger S, et al: ‘Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)’. Leukemia 24: 253-254, 2010
Glantz SA: Primer of Biostatistics (ed 6). New York, NY, McGraw-Hill Medical Publications, 2005
Marubini E, Valsecchi MG: Analysing Survival Data From Clinical Trials and Observational Studies. West Sussex, United Kingdom, John Wiley and Sons, 2004
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
Simon R, Makuch RW: A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias. Stat Med 3:35-44, 1984
Giovanella L, Toffalori E, Tozzoli R, et al: Multiplexed immunoassay of thyroglobulin autoanti-bodies in patients with differentiated thyroid carcinoma. Head Neck 34:1369-1371, 2012
Goshen Y, Stark B, Kornreich L, et al: High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 49:294-297, 2007
Nathan PC, Ness KK, Mahoney MC, et al: Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: A report from the childhood cancer survivor study. Ann Intern Med 153:442-451, 2010
Trebo MM, Attarbaschi A, Mann G, et al: Histiocytosis following T-acute lymphoblastic leukemia: A BFM study. Leuk Lymphoma 46:1735-1741, 2005
Szczepanski T, van der Velden VH, Waanders E, et al: Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: First evidence for genetic predisposition. J Clin Oncol 29:1643-1649, 2011
Zhang J, Ding L, Holmfeldt L, et al: The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157-163, 2012
Hartford C, Yang W, Cheng C, et al: Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia 21:2128-2136, 2007
Bolufer P, Collado M, Barragan E, et al: Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 136:590-596, 2007
Stanulla M, Dynybil C, Bartels DB, et al: The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: A matched-pair analysis from the ALL-BFM study group. Haematologica 92:1581-1582, 2007
Relling MV, Rubnitz JE, Rivera GK, et al: High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354:34-39, 1999
Stanulla M, Schaeffeler E, Möricke A, et al: Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood 114:1314-1318, 2009
Karran P, Attard N: Thiopurines in current medicalpractice:Molecularmechanismsandcontribu-tions to therapy-related cancer. Nat Rev Cancer 8:24-36, 2008
Toyoda Y, Manabe A, Tsuchida M, et al: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18:1508-1516, 2000
Kaspers GJ, Creutzig U: Pediatric acute myeloid leukemia: International progress and future directions. Leukemia 19:2025-2029, 2005
Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009